Blue Earth Diagnostics
2014
FOUNDED
PRIVATE
STATUS
91-100
EMPLOYEES
M&A
LATEST DEAL TYPE
$466M
LATEST DEAL AMOUNT
Description
Developer of molecular imaging agents designed to address unmet clinical needs and reliably inform diagnosis decisions. The company imaging agents can be used for PET imaging to detect and localize prostate cancer in men with the diagnosis of biochemical recurrence as well as in amino acid transport and radiopharmaceutical therapies, enabling medical practitioners to diagnose and treat brain and prostate cancer patients with improved efficiency.
Website
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Other Devices and Supplies
Other Industries
Monitoring Equipment
Biotechnology
Primary Office
- The Oxford Science Park
- Magdalen Centre, Robert Robinson Avenue
- Oxford OX4 4GA
- England, United Kingdom
+44 01865 000000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Blue Earth Diagnostics’s full profile, request a free trial.
Blue Earth Diagnostics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 01-Aug-2019 | $466M | 000.00 | 00000 | Completed | Profitable |
| 1. Early Stage VC | 11-Mar-2014 | 000.00 | 000.00 | Completed | Startup |
Blue Earth Diagnostics Executive Team (15)
6 Former Executives
You’re viewing 5 of 15 executives. Get the full list »Blue Earth Diagnostics Board Members (4)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Elisa Petris Ph.D | Syncona | Board Member | 000 0000 | |
| Jonathan Allis Ph.D | Blue Earth Diagnostics | Co-Founder, Board Member & Chief Executive Officer | 000 0000 | |
| Martin Murphy Ph.D | Self | Chairman | 000 0000 |
1 Former Board Member
You’re viewing 3 of 4 board members. Get the full list »